Understanding and Targeting the Pathophysiology of Youth-onset Type 2 Diabetes Clinical Centers (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-DK-21-002 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to ?c?r?e?a?t?e? ?a? ?c?l?i?n?i?c?a?l? consortium to recruit a cohort o?f early pubertal youth at risk for developing type 2 diabetes and study them th?r?o?ugh puberty. The ultimate goal of this undertaking will be to 1) develop more precise prediction of which individuals are truly at risk for developing you?t?h-onset T2D and identify determinants of progression from prediabetes to T2D so that, ultimately, targeted prevention approaches can be developed and tested; and 2) increase understanding ofthe physiologic dr...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 14, 2021 Category: Research Source Type: funding
Comprehensive Care for Adults with Type 2 Diabetes Mellitus from Populations with Health Disparities (R01 Clinical Trial Optional)
Funding for research focused on developing and testing strategies that adapt/implement recommended guidelines of comprehensive clinical care for individuals with Type 2 diabetes from health disparity populations. Geographic coverage: Nationwide -- National Institute on Minority Health and Health Disparities, National Institutes of Health, U.S. Department of Health and Human Services (Source: Funding opportunities via the Rural Health Information Hub)
Source: Funding opportunities via the Rural Health Information Hub - May 28, 2021 Category: American Health Source Type: funding
Comprehensive Care for Adults with Type 2 Diabetes Mellitus from Populations with Health Disparities (R01 Clinical Trial Optional)
Funding Opportunity PA-21-232 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support innovative multidisciplinary and multi-level research designed to develop and/or test interventions to optimize care of persons with Type 2 diabetes from populations with health/health care disparities concordant with evidence-based guidelines. NIH-designated health disparity populations include racial and ethnic minorities (Blacks/African Americans, Hispanics/Latinos, American Indians/Alaska Natives, Asians, Native Hawaiians and other Pacific Islanders), sexual and gender m...
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 26, 2021 Category: Research Source Type: funding
Institute and Center Award Rates and Funding Disparities
In 2011, Ginther et al. first demonstrated that African American and Black applicants to the National Institutes of Health received grant awards at a lower rate than their white counterparts (Ginther 2011). Since then, multiple studies have reproduced and extended this finding (Ginther 2011; Ginther 2016; Hoppe 2019; Erosheva 2020). Recently we reported that African American and Black (AAB) PIs are more likely to propose research on topics that are less likely to be funded (Hoppe 2019). We found that topic choice has little or no effect on whether an application is chosen for discussion, but after consideri...
Source: NIH Extramural Nexus - August 12, 2020 Category: Research Authors: Mike Lauer Tags: blog Open Mike Funding data Source Type: funding
Notice of Special Interest (NOSI): Comprehensive Care for Adults with Type 2 Diabetes Mellitus from Health Disparity Populations
Notice NOT-MD-20-026 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 11, 2020 Category: Research Source Type: funding
Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) Clinical Centers (Collaborative U01 Clinical Trial Required)
Funding Opportunity RFA-DK-20-501 from the NIH Guide for Grants and Contracts. The purpose of this Limited Competition Funding Opportunity Announcement (FOA) is to continue follow-up of the Diabetes Prevention Program Outcomes Study (DPPOS) cohort through a collaborative cooperative agreement. The Diabetes Prevention Program (DPP) was a multi-center controlled clinical trial examining the efficacy of treatments to prevent or delay the development of type 2 diabetes in a population at high risk. The DPP demonstrated that either weight loss through lifestyle change or the drug metformin could reduce the development of typ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 23, 2020 Category: Research Source Type: funding
Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) Biostatistics Research Center (BRC) (Collaborative U01 Clinical Trial Required)
Funding Opportunity RFA-DK-20-502 from the NIH Guide for Grants and Contracts. The purpose of this Limited Competition Funding Opportunity Announcement (FOA) is to continue follow-up of the Diabetes Prevention Program Outcomes Study (DPPOS) cohort through a collaborative cooperative agreement. The Diabetes Prevention Program (DPP) was a multi-center controlled clinical trial examining the efficacy of treatments to prevent or delay the development of type 2 diabetes in a population at high risk. The DPP demonstrated that either weight loss through lifestyle change or the drug metformin could reduce the development of typ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 23, 2020 Category: Research Source Type: funding
Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) Biostatistics Research Center (BRC) (Collaborative U01 Clinical Trial Required)
The purpose of this Limited Competition Funding Opportunity Announcement (FOA) is to continue follow-up of the Diabetes Prevention Program Outcomes Study (DPPOS) cohort through a collaborative cooperative agreement. The Diabetes Prevention Program (DPP) was a multi-center controlled clinical trial examining the efficacy of treatments to prevent or delay the development of type 2 diabetes in a population at high risk. The DPP demonstrated that either weight loss through lifestyle change or the drug metformin could reduce the development of type 2 diabetes by 58% and 31%, respectively, compared with placebo. Following the en...
Source: NIDDK Funding Opportunities - January 23, 2020 Category: Endocrinology Source Type: funding
Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) Clinical Centers (Collaborative U01 Clinical Trial Required)
The purpose of this Limited Competition Funding Opportunity Announcement (FOA) is to continue follow-up of the Diabetes Prevention Program Outcomes Study (DPPOS) cohort through a collaborative cooperative agreement. The Diabetes Prevention Program (DPP) was a multi-center controlled clinical trial examining the efficacy of treatments to prevent or delay the development of type 2 diabetes in a population at high risk. The DPP demonstrated that either weight loss through lifestyle change or the drug metformin could reduce the development of type 2 diabetes by 58% and 31%, respectively, compared with placebo. Following the en...
Source: NIDDK Funding Opportunities - January 23, 2020 Category: Endocrinology Source Type: funding
Limited Competition: NIDDK Program Projects (P01 Clinical Trial Optional)
Funding Opportunity PAR-20-075 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites submission of investigator-initiated Research Program Project Grant (P01) renewal (Type 2) applications. The proposed programs should address scientific areas relevant to the NIDDK mission including diabetes, selected endocrine and metabolic diseases, obesity, digestive diseases and nutrition, and kidney, urologic and hematologic diseases, as well as new approaches to prevent, treat and cure these diseases, including clinical research. A description of NIDDK scientific program areas can be foun...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 11, 2019 Category: Research Source Type: funding
Limited Competition: NIDDK Program Projects (P01 Clinical Trial Optional)
This Funding Opportunity Announcement (FOA) invites submission of investigator-initiated Research Program Project Grant (P01) renewal (Type 2) applications. The proposed programs should address scientific areas relevant to the NIDDK mission including diabetes, selected endocrine and metabolic diseases, obesity, digestive diseases and nutrition, and kidney, urologic and hematologic diseases, as well as new approaches to prevent, treat and cure these diseases, including clinical research. A description of NIDDK scientific program areas can be found at https://www.niddk.nih.gov/about-niddk/research-areas.National Institute of...
Source: NIDDK Funding Opportunities - December 11, 2019 Category: Endocrinology Source Type: funding
American Medical Association Community Health Grant
Grants for evidence-based projects that demonstrate focused, measurable results in community health and medical education programs, with priority given to services that target the prevention and reduction of type 2 diabetes and hypertension. Geographic coverage: Nationwide -- American Medical Association (Source: Funding opportunities via the Rural Health Information Hub)
Source: Funding opportunities via the Rural Health Information Hub - November 20, 2019 Category: American Health Source Type: funding
Limited Competition for the Accelerating Medicines Partnership (AMP) in Type 2 Diabetes Knowledge Portal (UM1 Clinical Trial Not Allowed)
Funding Opportunity RFA-DK-19-505 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites an application from the current awardee institution of the Accelerating Medicines Partnership in Type 2 Diabetes Knowledge Portal (AMP T2D KP). The AMP T2D program is a collaborative partnership between the NIH, pharmaceutical companies, and nonprofit organizations to develop new models for identifying and validating promising biological targets to serve as biomarkers and/or for drug discovery (www.nih.gov/research-training/accelerating-medicines-partnership-amp/type-2-diabetes). This is a o...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 27, 2019 Category: Research Source Type: funding
Understanding the Functional Contributions and Mechanisms of Type 2 Diabetes Disease-associated Variants (UM1 Clinical Trial Not Allowed)
Funding Opportunity RFA-DK-19-012 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications from integrative teams and individual investigators for large-scale complex multi-disciplinary Functional Genomics Projects (FGPs) to determine the contributions and mechanisms underlying the contribution of risk-associated variants and their downstream effector transcripts for type 2 diabetes (T2D). The intent is to generate knowledge and tools to enable the identification of putative biomarkers and therapeutic targets by future efforts. Genome-wide association studies (GWAS...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 27, 2019 Category: Research Source Type: funding
Limited Competition for the Accelerating Medicines Partnership (AMP) in Type 2 Diabetes Knowledge Portal (UM1 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) invites an application from the current awardee institution of the Accelerating Medicines Partnership in Type 2 Diabetes Knowledge Portal (AMP T2D KP). The AMP T2D program is a collaborative partnership between the NIH, pharmaceutical companies, and nonprofit organizations to develop new models for identifying and validating promising biological targets to serve as biomarkers and/or for drug discovery (www.nih.gov/research-training/accelerating-medicines-partnership-amp/type-2-diabetes). This is a one-time FOA to provide funds to the AMP T2D KP to continue the development of the ...
Source: NIDDK Funding Opportunities - September 27, 2019 Category: Endocrinology Source Type: funding
